| Source: |
| Type: |
| Gut microbiome may affect responses to numerous forms of cancer therapy. The gut microbiota plays a multifaceted role in cancer biology, influencing tumor development, progression, and patient prognosis. Dysbiosis and specific microbial populations have been linked to various cancers, with implications for patient outcomes. While the relationship between gut microbiota and cancer prognosis is an active area of research, it holds promise for the development of microbiome-based biomarkers and therapeutic strategies in oncology. |
| Stomach/Gastric Cancer |
| 5356- | AL, | Therapeutic role of allicin in gastrointestinal cancers: mechanisms and safety aspects |
| - | Review, | GC, | NA |
| 2667- | AL, | Allicin in Digestive System Cancer: From Biological Effects to Clinical Treatment |
| - | Review, | GC, | NA |
| 1032- | Buty, | Gut microbiome-derived butyrate inhibits the immunosuppressive factors PD-L1 and IL-10 in tumor-associated macrophages in gastric cancer |
| - | in-vivo, | GC, | AGS |
| 4846- | Uro, | Urolithin A exerts anti-tumor effects on gastric cancer via activating autophagy-Hippo axis and modulating the gut microbiota |
| - | in-vivo, | GC, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:28 Cells:% prod#:% Target#:350 State#:% Dir#:2
wNotes=0 sortOrder:rid,rpid